Conference Correspondent

PREAMBLE is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with 1 line of prior therapy.
A leading cancer clinic has developed an innovative response-adapted treatment protocol for newly diagnosed patients with multiple myeloma.
Preliminary data suggest that subcutaneous delivery of daratumumab in patients with relapsed/refractory multiple myeloma is well-tolerated and yields similar response rates to intravenous administration of the drug.
Daratumumab in combination with lenalidomide plus dexamethasone specifically induces robust increases in T-cell clonality. The finding provides support for an immune modulatory mechanism of daratumumab.
Outcomes of patients with relapsed/refractory multiple myeloma are poor, but are improving as treatment options expand.
Compared with standard-of-care therapies delivered in a real-world setting, daratumumab monotherapy extends overall survival in patients with heavily pretreated and highly refractory multiple myeloma.

Chicago, IL—The anaplastic lymphoma kinase (ALK) mutation is a target for tyrosine kinase therapies in several cancers, including non–small-cell lung cancer (NSCLC). Since 2011, several ALK inhibitors have been approved, and more are in the pipeline, but many questions remain for managing patients with ALK-positive NSCLC.

Chicago, IL—A clear set of standard operating procedures is at the heart of US Pharmacopeial Convention Chapter 800 (USP 800) compliance, according to Carol Yarrington, PharmD, BCOP, Oncology and Infusion Pharmacy Coordinator and Clinical Oncology Pharmacist, St. Joseph Mercy Health System, Ann Arbor, MI.

Boston, MA—Hypofractionated radiotherapy achieves comparable quality of life compared with conventional radiotherapy, and has the advantages of shorter treatment time, greater convenience to the patient, and less cost to the healthcare system compared with conventional radiotherapy. The hypofractionated radiotherapy schedule is value-based, noted experts at the 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Boston, MA—It is well-recognized that radiation-induced symptoms can be extremely severe for patients with head and neck cancer. Although “magic mouthwash” (ie, diphenhydramine plus lidocaine plus antacid [DLA]) is frequently used for the treatment of oral mucositis associated with radiotherapy to the head and neck, until now there has been no solid evidence for this approach.

Page 10 of 28
Results 91 - 100 of 273